Drug news
Takeda re-submits Nesina and Nesina plus Actos at FDA for Type 2 Diabetes
Takeda has re-filed new drug applications at the FDA for its antidiabetic Nesina (alogliptin) and a fixed-dose combination of the dipeptidyl peptidase IV inhibitor with pioglitazone (Takeda's Actos).Updated additional postmarketing data from outside the US (from Japan) and significant new data from three Phase III studies in its ongoing global clinical trial programme had been included in the resubmissions.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins